Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125408 · ClinicalTrials.gov registry record
Clinical Performance Evaluation of DxN HCV Assay
A clinical trial, sponsored by Beckman Coulter.
- Terminated
- Registry status
- 210
- Enrollment target
NCT03125408 is a clinical trial that was terminated before completion, run by Beckman Coulter. The registered enrollment target is 210 participants.
The verdict
NCT03125408 was terminated before completion, sponsored by Beckman Coulter.
- TERMINATED
- Registry status
- 210 participants
- Enrollment target
Study Summary
The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HCV Assay for plasma samples in the intended use population.
Interventions
- DIAGNOSTIC_TEST HCV Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2012-05-02 |
| Est. Completion | 2017-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125408
The ClinicalTrials.gov registry entry for NCT03125408 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beckman Coulter, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HCV Assay is the first listed.
NCT03125408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03125408 about?
NCT03125408 is a clinical study titled "Clinical Performance Evaluation of DxN HCV Assay". The DxN Hepatitis C Virus (HCV) Assay is an in vitro diagnostic assay intended as an aid in the management of of HCV-infected individuals undergoing antiviral therapy. The purpose of the study is to establish the clinical performance of the DxN HCV Assay for plasma samples in the intended use popula...
What is the current status of trial NCT03125408?
This trial is currently terminated. The enrollment target is 210 participants. The study started on 2012-05-02. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03125408?
The interventions under investigation include: HCV Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03125408?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.